Evidence map›Paper›PMID 34493923›Full record

ArticleProcess biochemistry (Barking, London, England)2021

Clean and folded: Production of active, high quality recombinant human interferon-λ1.

Aram Shaldzhyan, Yana Zabrodskaya, Nikita Yolshin, Tatiana Kudling, Alexey Lozhkov, Marina Plotnikova, Edward Ramsay, Aleksandr Taraskin, Peter Nekrasov, Mikhail Grudinin and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Process biochemistry (Barking, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Aram ShaldzhyanSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Yana ZabrodskayaSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Nikita YolshinSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Tatiana KudlingCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Alexey LozhkovSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Marina PlotnikovaSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Edward RamsaySmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Aleksandr TaraskinSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Peter NekrasovSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Mikhail GrudininSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Andrey VasinSmorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.
Ministry of Health of the Russian Federation · RUPeter the Great St. Petersburg Polytechnic University · RUUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type III interferons exhibit antiviral activity against influenza viruses, coronaviruses, rotaviruses, and others. In addition, this type of interferon theoretically has therapeutic advantages, in comparison with type I interferons, due to its ability to activate a narrower group of genes in a relatively small group of target cells. Hence, it can elicit more targeted antiviral or immunomodulatory responses. Obtaining biologically-active interferon lambda (hIFN-λ

Indexed as

Cation exchange chromatographyImmobilized metal affinity chromatographyInterferon-lambdaRefolding

Identifiers

PMID34493923
PMCPMC8411590
OpenAlexW3198001080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.